These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 588468)

  • 1. Vasoconstrictor activities and bio-availabilities of seven proprietary corticosteroid creams assessed using a non-occluded multiple dosage regimen; clinical implications.
    Barry BW; Woodford R
    Br J Dermatol; 1977 Nov; 97(5):555-60. PubMed ID: 588468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprietary hydrocortisone creams. Vasoconstrictor activities and bio-availabilities of six preparations.
    Barry BW; Woodford R
    Br J Dermatol; 1976 Oct; 95(4):423-5. PubMed ID: 974028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications.
    Woodford R; Haigh JM; Barry BW
    Dermatologica; 1983; 166(3):136-40. PubMed ID: 6852325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments.
    Barry BW; Woodford R
    Br J Dermatol; 1975 Nov; 93(5):563-71. PubMed ID: 1203181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations.
    Gibson JR; Kirsch J; Darley CR; Burke CA
    Br J Dermatol; 1983 Jul; 109 Suppl 25():114-6. PubMed ID: 6860578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dilution of proprietary corticosteroid ointments--an attempt to evaluate relative clinical potencies.
    Gibson JR; Darley C; Kirsch J; Saihan EM; Neild VS
    Br J Dermatol; 1982 Apr; 106(4):445-7. PubMed ID: 7073968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
    Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
    Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of skin-colour changes induced by topical corticosteroid preparations using the Minolta Chroma Meter.
    Queille-Roussel C; Poncet M; Schaefer H
    Br J Dermatol; 1991 Mar; 124(3):264-70. PubMed ID: 2018732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous vasoconstrictor response to glucocorticoids in asthma.
    Brown PH; Teelucksingh S; Matusiewicz SP; Greening AP; Crompton GK; Edwards CR
    Lancet; 1991 Mar; 337(8741):576-80. PubMed ID: 1671942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the skin penetration properties of different carrier vehicles for topically applied cortisol.
    Ayres PJ; Hooper G
    Br J Dermatol; 1978 Sep; 99(3):307-17. PubMed ID: 708599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel intraindividual evaluation of the vasoconstrictory action and the anti-allergic activity of topical corticosteroids.
    Seidenari S; Di Nardo A; Mantovani L; Giannetti A
    Exp Dermatol; 1997 Apr; 6(2):75-80. PubMed ID: 9209888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
    Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
    Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potency assessment of topical corticoids in the vasoconstrictor assay and on tuberculin-induced inflammation.
    Schalla W; Schorning S
    Skin Pharmacol; 1991; 4(3):191-204. PubMed ID: 1768431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity?
    Stoughton RB; Wullich K
    Arch Dermatol; 1989 Nov; 125(11):1509-11. PubMed ID: 2817915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reflectance spectrophotometric quantification of skin colour changes induced by topical corticosteroid preparations.
    Feather JW; Ryatt KS; Dawson JB; Cotterill JA; Barker DJ; Ellis DJ
    Br J Dermatol; 1982 Apr; 106(4):437-43. PubMed ID: 7073967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative blanching activities of locally manufactured proprietary fluocinolone acetonide topical preparations.
    Coleman GL; Magnus AD; Haigh JM; Kanfer I
    S Afr Med J; 1979 Sep; 56(11):447-9. PubMed ID: 399090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of proprietary corticosteroid containing ointments.
    Trikam DS; Morton DJ
    Cent Afr J Med; 1985 Mar; 31(3):57-8. PubMed ID: 4016908
    [No Abstract]   [Full Text] [Related]  

  • 18. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations.
    Gibson JR; Kirsch JM; Darley CR; Harvey SG; Burke CA; Hanson ME
    Br J Dermatol; 1984 Jul; 111 Suppl 27():204-12. PubMed ID: 6378245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chamber vasoconstrictor assay. I. Comparison with occluded and unoccluded tests using four corticosteroids.
    Somerma S
    Clin Exp Dermatol; 1980 Jun; 5(2):191-6. PubMed ID: 7438514
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.
    Hoffmann K; Auer T; Stücker M; Hoffmann A; Altmeyer P
    J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):137-42. PubMed ID: 9553910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.